You do not have permission to edit this page, for the following reasons:
{{DrugProjectFormSinglePage |authorTag={{Ammu}} |OTC=Yes |genericName=sulfur and resorcinol |aOrAn=an |drugClass=anti [[acne]] agent |indicationType=treatment |indication=management of [[acne]] |adverseReactions=[[hypersensitivity]] |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span> |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i> * Content <!--Adult Indications and Dosage--> <!--FDA-Labeled Indications and Dosage (Adult)--> |fdaLIADAdult=* Uses for the management of [[acne]] * Penetrates pores to control [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads * Helps keep skin clear of new [[acne]] blemishes, [[acne]] pimples, blackheads and whiteheads. =====Directions===== * Shake well * Cleanse he skin thoroughly before applying the medication * Cover the entire affected area with a thin layer one to three times daily * Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor * If bothersome dryness or peeling occurs, reduce application to once a day or every other day. |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. <!--Non–Guideline-Supported Use (Adult)--> |offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients. <!--Pediatric Indications and Dosage--> <!--FDA-Labeled Indications and Dosage (Pediatric)--> |fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients. <!--Off-Label Use and Dosage (Pediatric)--> <!--Guideline-Supported Use (Pediatric)--> |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. <!--Non–Guideline-Supported Use (Pediatric)--> |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients. <!--Contraindications--> |contraindications=<!--Warnings--> |warnings=* For external use only * Flammable, Keep away from fire or flame * Do not use on broken skin, on large areas of the body |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label. |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label. |drugInteractions=<!--Use in Specific Populations--> |useInPregnancyFDA=* '''Pregnancy Category''' |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category''' There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery. |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised. <!--Administration and Monitoring--> |administration=* [[Topical]] |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label. <!--IV Compatibility--> |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label. <!--Overdosage--> |overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label. <!--Pharmacology--> <!--Drug box 2--> |drugBox={{chembox2 | Verifiedfields = changed | verifiedrevid = 415763656 | Name = Resorcinol | ImageFileL1 = Resorcinol.png | ImageNameL1 = Skeletal formula | ImageFileR1 = Resorcinol-3D-balls.png | ImageNameR1 = Ball-and-stick model | IUPACName = Benzene-1,3-diol | OtherNames = Resorcin<br />m-dihydroxybenzene; 1,3-benzenediol; 1,3-Dihydroxybenzene; 3-Hydroxyphenol; m-hydroquinone; m-benzenediol; 3-hydroxycyclohexadien-1-one | Section1 = {{Chembox Identifiers | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 27810 | SMILES = c1cc(cc(c1)O)O | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4878 | PubChem = 5054 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 24147 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = YUL4LO94HK | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00133 | InChI = 1/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H | InChIKey = GHMLBKRAJCXXBS-UHFFFAOYAB | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C6H6O2/c7-5-2-1-3-6(8)4-5/h1-4,7-8H | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = GHMLBKRAJCXXBS-UHFFFAOYSA-N | CASNo_Ref = {{cascite|correct|CAS}} | CASNo = 108-46-3 | UNNumber = 2876 | ATCCode_prefix = D10 | ATCCode_suffix = AX02 | ATC_Supplemental = {{ATC|S01|AX06}} }} | Section2 = {{Chembox Properties | Formula = C<sub>6</sub>H<sub>6</sub>O<sub>2</sub> | MolarMass = 110.1 g/mol | Appearance = White solid | Density = 1.28 g/cm<sup>3</sup>, solid | Solubility = 110 g/100 mL at 20 °C | MeltingPtC = 110 | BoilingPtC = 277 | pKa = 9.15<ref>Gawron, O., Duggan, M., Grelechi, C., ''J. Anal. Chem.'', '''1952''', ''24'', 969.</ref> }} | Section3 = {{Chembox Structure | Dipole = }} | Section7 = {{Chembox Hazards | ExternalMSDS = | FlashPtF = 261 | EUClass = Harmful ('''Xn''')<br />Dangerous for<br />the environment ('''N''') }} }} |mechAction=<!--Structure--> |structure=<!--Pharmacodynamics--> |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label. <!--Pharmacokinetics--> |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label. <!--Nonclinical Toxicology--> |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label. <!--Clinical Studies--> |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label. <!--How Supplied--> |packLabel=[[File:Resorcinol 01.jpg|thumb|none|400px|This image is provided by the National Library of Medicine.]] [[File:Resorcinol 02.png|thumb|none|400px|This image is provided by the National Library of Medicine.]] |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label. <!--Precautions with Alcohol--> |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. <!--Brand Names--> |brandNames=* ACNOTEX ACNE TREATMENT®<ref>{{Cite web | title = ACNOTEX ACNE TREATMENT - sulfur and resorcinol lotion | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89bc8aff-8cd7-41ed-8619-11cd2dd5ffde }}</ref> <!--Look-Alike Drug Names--> |drugShortage= }} <!--Pill Image--> <!--Label Display Image--> <!--Category--> [[Category:Drug]] [[Category:IARC Group 3 carcinogens]]
Free text:
Save page Show preview Show changes Cancel